Chinese under watch for novel coronavirus dies in San Lazaro Hospital | Inquirer News

Chinese under watch for novel coronavirus dies in San Lazaro Hospital

By: - Reporter / @ConsINQ
/ 02:55 PM January 29, 2020

MANILA, Philippines — A 29-year-old Chinese man, who is under investigation for suspected novel coronavirus infection has died of pneumonia while undertaking treatment at the San Lazaro Hospital in Manila, an official from the hospital announced on Wednesday.

San Lazaro Hospital director Dr. Edmundo Lopez said the victim, who is from Yunnan, China, died on Wednesday at 7 a.m. The patient was admitted last Monday.

“Early this morning around 7 a.m., We have person under investigation, hindi pa confirmed for nCoV, na namatay. [He]was admitted last Monday,” Lopez said in a press briefing.

Article continues after this advertisement

(Early this morning around 7 a.m., We have a person under investigation, who was not confirmed for nCoV, has died. He was admitted last Monday]

FEATURED STORIES

Lopez also noted that the samples from the Chinese victim were already sent to the Research Institute for Tropical Medicine (RITM) in Muntinlupa for an initial test for suspected novel coronavirus infection.

“Specimens have been taken. May test na natira ang RITM (There are still tests in RITM) for detection of coronavirus,” Lopez said.

Article continues after this advertisement

Lopez said the Chinese patient had varying symptoms including enlarged lymph nodes.

Edited by MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: China, Nation

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.